Commercial Credit Report for Farmak AT

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Farmak AT is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Farmak AT
vul. Frunze (Kyrylivs'ka), 63
Phone: +380 442391940p:+380 442391940	KIEV, 04080 Ukraine	Ticker: FARMFARM

On March 4, 2022, CreditRiskMonitor.com, Inc. suppressed the FRISK® score of all publicly listed Russian and Ukrainian-based companies trading domestically due to the closure of their respective stock markets. The halt of trading in a counterparty’s securities is never a positive signal for creditors or suppliers, but especially in situations where the prices of those securities were above book value before the halt. The loss of liquidity optionality from equity markets inherently increases the bankruptcy risks for any business and dealing with businesses who have lost this financing option should be strongly scrutinized. Stock Market data is one of the essential components used in the daily calculation of the FRISK®. The omission of this data can reduce the score's effectiveness in predicting bankruptcy risk for companies trading within these markets. In addition, any analysis based on previously reported financials should be used with caution in this environment. We are continuing to monitor the Russia-Ukraine conflict and plan to reevaluate the appropriateness of the FRISK® when the affected exchanges have reopened and trading in securities resumes.

Business Summary

Farmak PAT (Farmak OJSC) is a Ukraine-based company involved in the chemical and pharmaceutical industry. The Company's product portfolio includes approximately 150 names in various dosage forms: parenteral dosage forms, drops, ointments, tablets and capsules. It is also involved in the production of pharmaceuticals for veterinarian use, pharmaceutical substances synthesis, contract manufacturing, and scientific research. The Company owns such facilities as equipment for labeling and packaging ampoules, production section for drags dosage forms of medicines, and a workshop for ointments, creams, pastes, and gels. Farmak PAT operates on the markets of Ukraine, the Baltic countries, Bulgaria, the Commonwealth of Independent States countries and Poland.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
9/30/2021	12/31/2020	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairwoman of the Supervisory Board - Representative of Farmak International Holding GMBH	Filia I.Zhebrovska	69
General Director (CEO), Member of the Supervisory Board - Representative of Farmak International Ho	Volodymyr H.Kostiuk		7/25/2018	4/19/2018
Technical Director	Hryhorii V.Kostiuk	52	1/1/2012
9 additional Officers and Directors records available in full report.

Business Names

Business Name
FARM
Symphar S.p Z.o.o.

General Information

Number of Employees:	2,931	(As of 9/30/2021)
Outstanding Shares:	6,857,254	(As of 9/30/2021)
Stock Exchange:	KSE
Fax Number:	+380 444171055

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN